Metabolic disrupters, phages, and other approaches are going to be needed to treat the broadest possible range of patients infected by bacterial pathogens resistant to multiple drugs.

Phage therapy is but one example of using biological entities to reduce our reliance on antibiotics and other failing chemical solutions.

In Chapter 3, “The Enemy of Our Enemy Is Our Friend: Infecting the Infection,” author Emily Monosson makes the case for bacteriophage therapy in the treatment of infectious disease.

Understanding the biological roots of cooperation might help resolve some of the biggest scientific challenges we face.

Phage therapy to combat bacterial infections is garnering attention for the second time in 100 years, but solid clinical support for its widespread use is still lacking.

Researchers develop a CRISPR-based, two-phage system that sensitizes resistant bacteria to antibiotics and selectively kills any remaining drug-resistant bugs. 

Researchers are putting a fresh crop of phage-based products to agricultural and medical use, on farms and in early-stage clinical trials.